Seres Therapeutics (NASDAQ:MCRB) held its reconvened 2026 Annual Meeting of Stockholders on July 8, with stockholders approving all five proposals presented at the meeting, according to the company’s preliminary vote report.
Tom DesRosier, Executive Vice President, Chief Legal Officer and Secretary of Seres Therapeutics, chaired the meeting. He said the company had a quorum present, with more than a majority of shares represented online or by proxy. Seres had 9,632,111 shares of common stock held of record as of April 13, 2026, the record date for the meeting.
Directors Elected to Class II Board Seats
DesRosier noted that several members of the board were present for the virtual meeting, including Dennis Ausiello, Berenson, Willard Dere, Fraser, Kurt Graves, Rob Rosiello and Eric Shaff.
Auditor Ratified and Executive Pay Approved
Stockholders also ratified the Audit Committee’s appointment of PricewaterhouseCoopers as Seres Therapeutics’ independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Holly Reeves of PricewaterhouseCoopers was available during the meeting to respond to appropriate questions through the meeting portal.
In addition, shareholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting of Stockholders.
Incentive Plan Amendment Approved
The company said stockholders approved an amendment and restatement of the Seres Therapeutics, Inc. 2025 Incentive Award Plan to increase the number of shares available for issuance under the plan.
A fifth proposal, allowing for adjournment of the annual meeting if needed to solicit additional proxies for the incentive plan proposal, was also approved. However, DesRosier said an adjournment was not necessary because the incentive plan amendment had passed.
No Stockholder Questions Submitted
Following the formal business portion of the meeting, Kristen Grogan, Vice President and Assistant General Counsel at Seres Therapeutics, said no stockholder questions had been submitted that complied with the meeting’s rules of conduct.
DesRosier said the final report of the Inspector of Election will be kept with the company’s annual meeting records. He added that the final vote tally will be published within four business days in a current report on Form 8-K to be filed with the Securities and Exchange Commission.
About Seres Therapeutics (NASDAQ:MCRB)
Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.
Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.
